Apomorphine administered subcutaneously has provided clinicians with an effective option for the rapid resolution of the symptoms of Parkinson's disease (PD) for over a quarter of a century. It is available for use either as an intermittent injection or a continuous infusion, depending on the severity of the patient's symptoms. This satellite symposium, held during the 18th International Congress of Parkinson's Disease and Movement Disorders in Stockholm, Sweden, from 8-12 June 2014, and chaired by Professor Andrew Lees, set out to review the extensive clinical experience of subcutaneous apomorphine in the management of PD accumulated over the past 25 years. It also aimed to explore why it continues to play such a valuable therapeutic role in this setting. The presenters highlighted key clinical data demonstrating why apomorphine is an effective choice for the management of both motor and non-motor symptoms in PD. Results from the limited number of comparative studies of apomorphine continuous infusion with other therapies for complex PD suggest that it has a robust motor effect, resulting in a reduction of OFF periods comparable to that achieved with more invasive options such as intrajejunal levodopa infusion or deep brain stimulation. In a large European study, apomorphine infusion has been shown to provide similar improvements in health-related quality of life to intrajejunal levodopa infusion but with a superior side-effect profile. In addition, apomorphine infusion has demonstrated beneficial non-motor effects in PD patients and reports suggest it is associated with low rates of impulse control disorders (ICDs). The motor fluctuations that occur over time in PD patients treated with oral levodopa present a management challenge as the disease progresses. Many PD patients experience these OFF periods despite optimised oral therapy and the use of multiple medications. They are due to both end-of-dose wearing OFF and delayed time to ON (TTO). A prolonged TTO is common in PD patients who have gastroparesis (delayed gastric emptying) whereby the levodopa dose is delayed exiting the stomach and is slow in reaching its site of absorption in the small intestine. Alternative non-oral formulations that avoid the gastrointestinal route, such as subcutaneous apomorphine intermittent injection, have therefore been investigated for the relief of motor fluctuations in this setting. Interim results from the ongoing Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) study have shown that subcutaneous apomorphine injection is a valuable treatment option in PD patients with morning akinesia. This is due to a delayed onset of levodopa dose as it produces a rapid and reliable TTO, with 95 % of patients achieving at least a 20-minute reduction in TTO and an average reduction of 40 minutes. Patients also experienced improvements in Unified Parkinson's Disease Rating Scale (UPDRS) motor score and Hoehn and Yahr stage, as well as measures of quality of life and global impression of severity.
Introduction to Apomorphine and its Role in the Treatment of Parkinson's Disease
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Apomorphine is a highly-potent dopamine agonist (DA) that, unlike other clinically available compounds in this class, selectively acts on both D1 and D2 dopamine receptors and has been shown in a number of published clinical trials to achieve antiparkinsonian efficacy comparable to that of orally administered levodopa. 1 As far back as the 1950s, apomorphine was used to treat PD, long before its dopaminergic properties were fully understood and levodopa was developed. 2 Subsequently, in the late 1960s,
Cotzias and colleagues, aware of some of the shortcomings of levodopa in PD treatment, began to investigate other dopaminergic compounds and conducted clinical investigations into apomorphine in PD patients.
They found that tremor responded well to apomorphine therapy, that it reduced dyskinesias in levodopa-treated patients and that it had possible anti-psychotic properties. 3 The product was not developed further at that time as a therapy for PD, possibly due to both the emergence of oral dopaminergic drugs and the reluctance of neurologists to use an injectable formulation, but also due to its emetic properties. Subsequently, as a result of new pump technology in the field of diabetes and the availability of the anti-emetic domperidone, a clinical trial of apomorphine infusion for the management of Parkinsonian ON-OFF oscillations was undertaken by Stibe and colleagues. 4 Published in 1988, this pivotal trial confirmed that apomorphine was the only clinically available DA that was equipotent to levodopa and it was subsequently licensed for the treatment of PD in the UK. Since that time, a range of randomised, controlled clinical trials (using apomorphine injection) and open, uncontrolled studies (using apomorphine infusion) have confirmed it as a highly effective therapy to help manage refractory motor fluctuations, with thousands of PD patients throughout the world benefitting from its use. Apomorphine infusion has also been shown to improve drug-induced dyskinesias, allowing a reduction in the oral levodopa dose. 5 Nowadays, apomorphine is recognised by clinicians as an established therapy, backed by many patient-years of experience, which still has considerable value in helping to manage the complex problems they face in treating PD patients in their daily clinical practice.
This satellite symposium, held during the 18th International Congress of Parkinson's Disease and Movement Disorders, reviewed the extensive clinical experience with subcutaneous apomorphine in PD patients that has accumulated over the past 25 years and explored why it continues to play such a valuable role in treatment of this disease.
While the management of PD focuses primarily on addressing motor symptoms, there is also a broad range of non-motor symptoms (NMS)
that compromise health-related quality of life (QoL) in PD patients. [6] [7] [8] In his presentation, Professor K Ray Chaudhuri discussed comparative data on both motor and non-motor effects of conventional non-oral/ transdermal therapies in advanced PD and the reported beneficial effects of subcutaneous apomorphine in this setting, particularly in terms of its side-effect profile in comparison to other agents.
Morning akinesia is a common but under-recognised symptom in PD patients, which occurs in almost 60 % of subjects 9 Table 1 ). Notably, there were significant improvements in specific NMS such as hyperhidrosis, urinary function, fatigue, mood and sleep. In addition, apomorphine was tolerated in patients with visual hallucinations, illusions and paranoid ideations. The levodopa equivalent dose also decreased significantly in apomorphine-treated patients.
Professor Chaudhuri noted, in particular, the significant effect of apomorphine on urinary symptoms observed in this study, notably on urinary urgency, frequency and nocturia. These observations are supported by the results of preliminary studies in animal models suggesting that -8dopamine receptor agonists, particularly those which have both a D1 and D2 effect such as apomorphine, can improve bladder function. 12, 13 In the clinical setting, a study of 10 PD patients also confirmed that apomorphine could be a useful drug for the management of urinary symptoms. The investigators found that voiding efficiency improved after subcutaneous apomorphine injection, with an increase in mean and maximum flow rates in nine patients and a reduction in post-micturition residual volume in six.
14 These preliminary findings require confirmation in larger studies.
Apomorphine Infusion versus Intrajejunal Levodopa Infusion
Treatment with apomorphine infusion plus oral levodopa has been compared with intrajejunal levodopa infusion monotherapy in a small, anecdotal study of four PD patients with motor fluctuations. 15 Although not a true comparative study, the results suggested that the levodopa infusion was able to provide greater motor benefits than apomorphine infusion. More recently, as part of the Movement Disorder Society (MDS) Non-Motor Study Group, the EuroInf study, a large-scale, open-label, multicentre, international, real-life study has been undertaken to compare apomorphine infusion (n=43) with intrajejunal levodopa infusion (n=44) at 12 centres throughout the UK, Italy, Sweden, Germany, Slovenia, Austria and Denmark. 16 There were no significant differences at baseline between the two groups in terms of age, gender, duration of PD, Hoehn & Yahrbased severity level, UPDRS sections III and IV, NMSS domains and total score, PDQ-8 summary index and levodopa equivalent dose.
Both treatments showed significant benefits on UPDRS part III and IV motor scores. Notably, in contrast to the previous study by Nyholm and colleagues, 15 this study showed both agents to be equivalent in terms of their motor effects (see Table 2 ). Both compounds also had robust effects on the NMSS total score and on QoL measures (PDQ-8). When individual NMS were analysed, sleep and fatigue appeared to show greater improvements with levodopa infusion, while mood and apathy showed greater improvements with apomorphine infusion.
Professor Chaudhuri noted that when selecting therapy for PD patients it was important to take into consideration the side-effect profile of any treatment as this may affect both the overall cost of therapy and its tolerability. In the EuroInf study, after 3 years of follow-up, the most common side effect with apomorphine therapy was skin nodules. However, Professor Chaudhuri noted that none required discontinuation of therapy.
He added that in his centre these were not a problem provided good skin care was exercised. Other reported adverse effects with apomorphine infusion were failure of therapy (three patients), incident impulse control disorders (ICDs; two patients) and severe somnolence (two patients), which required discontinuation of therapy in one patient. In the intrajejunal levodopa infusion arm, reported side effects included demyelinating polyneuropathy (three patients), which required discontinuation of therapy in two patients, and severe weight loss/malabsorption syndrome (seven patients), which is a late-onset effect and can occur after about 2 years of therapy. In addition, some patients experienced tube detachment and two patients developed peritonitis, one of whom subsequently died. No ICDs were observed in this treatment group and in four patients who had preexisting ICDs these were resolved. Professor Chaudhuri considered that overall apomorphine infusion therapy had the better side-effect profile of the two treatment options.
ICDs in are common in patients with PD with a reported frequency of 13.6 %, 17 was severe in one patient who had to discontinue treatment. 18 In an audit of apomorphine use in Ireland, Magennis et al. found that pre-existing ICDs were resolved in five patients after they commenced treatment. 19 In a recent single-centre, observational study of 41 PD patients receiving apomorphine infusion in Professor Chaudhuri's own institution, seven had pre-existing ICDs that resolved or attenuated after the initiation of therapy. 20 Six new ICDs developed, including excessive eating, compulsive shopping and Internet use, hypersexuality and punding.
However, in two cases patients were also being treated with rotigotine so the relationship between these ICDs and apomorphine is unclear. From the results, the authors concluded that apomorphine infusion appears to have a relatively low risk for the development of ICD -around 8 % which is lower than has been reported with oral DAs -with discontinuation of therapy required only in 2.4 % of cases. fluctuations that are due not only to end-of-dose wearing off but also to delayed TTO. Until recently, the focus of treatment in this situation has been on trying to improve end-of-dose wearing off while minimising peakdose dyskinesias. However, studies now show that delayed TTO is in fact a major contributor to OFF time, being more than twice the duration of wearing off, so it is important that this aspect is also addressed to ensure that patients' symptoms are managed quickly and reliably. 26 Professor
Isaacson illustrated the problem of the unreliable pharmacokinetics of levodopa and the resulting effect on the clinical response with reference to a study by Professor Fabrizio Stocchi (unpublished data) looking at levodopa plasma levels over the course of a day in a patient taking a dose every 2.5 hours. The response to each dose showed considerable variation: some doses did not increase levodopa plasma levels to within the therapeutic range, resulting in the patient being in a prolonged OFF state, whereas others produced an increase to the point where dyskinesias could occur. Delayed TTO following a levodopa dose can, therefore, result in morning akinesia, postprandial akinesia and dose failure where the dose of levodopa does not work at all.
Early morning OFF (EMO) periods are common in PD patients, being reported to occur in up to 60 % of those with motor fluctuations. 9, 10 They are often the first manifestation of motor fluctuations and are known to have a significant negative impact on a patient's ability to undertake daily activities and on their QoL. 10 In the recent European Parkinson's Disease Association (EUROPAR) study, the prevalence and characteristics of EMO periods were investigated in a series of 320 PD patients with a mean disease duration of seven years. 9 EMO periods were found to be present in 59.7 % of patients and occurred throughout the course of the disease at all stages, in mild, moderate and severe PD patients (see Figure 1 ).
In the patients who experienced EMO, the investigators found not only motor symptoms (morning akinesia) but also a range of NMS. A total of 88 % had EMO with mixed motor symptoms and NMS, while 12 % had pure motor EMO. The most common NMS were urinary urgency, anxiety, pain, dribbling, low mood and paresthesia, all of which complicate the clinical picture of patients with EMO.
Professor Isaacson went on to consider the reasons underlying the delayed TTO of a morning levodopa dose. It is known that the gastrointestinal (GI)
system in PD patients is dysfunctional and that GI symptoms can occur even before PD is clinically diagnosed. 27 Gastroparesis (delayed emptying of the stomach) is a common GI problem in patients with PD at both early and late disease stages and may be one of the underlying causes of delayed TTO. 27, 28 Impaired intestinal absorption may also be a contributing factor as amino acids in dietary proteins can compete with levodopa for intestinal absorption and transport across the blood-brain barrier, thus limiting its efficacy. 29 However, since protein is not typically present on awakening, morning akinesia is most probably due to gastroparesis resulting in delayed gastric emptying of the dose of levodopa. Classic symptoms of gastroparesis include nausea, vomiting, early satiety, postprandial fullness and abdominal discomfort, but the presence of delayed TTO is possibly one of the major features of gastroparesis in PD, resulting from the delay in emptying of levodopa from the stomach into the proximal small intestine where it is absorbed.
In light of these GI factors in PD patients, Professor Isaacson considered that alternative formulations or routes of administration need to be considered to ensure that the PD medication is efficiently absorbed and able to exert its clinical effect. Strategies aimed at enhancing the delivery of levodopa to the proximal small intestine by the use of liquid, dispersible, modified or higher-dose levodopa have been employed.
However, in PD patients who have gastroparesis, emptying of both solids and liquids may be impaired. 30 Recent studies have highlighted the importance of considering pharmacokinetic factors when analysing delayed TTO. In patients with gastroparesis, the normal rise in plasma levodopa levels after oral administration has been shown to be delayed and have a lower peak, prolonging the TTO. 31 The pharmacokinetics of levodopa have been investigated in 19 patients with advanced PD for more than 10 years, with and without a delayed response to the first dose in the morning. other pharmacokinetic parameters showed any significant differences.
The authors concluded that the difference in plasma concentrations between the two groups was likely to be due to delayed gastric emptying.
Subcutaneous apomorphine injection is one option that can be used to avoid the oral route of administration in PD patients who have gastroparesis. Apomorphine injection has previously been shown in clinical trials to provide rapid, effective relief of OFF episodes, as measured by improvements in UPDRS motor scores at 20, 40 and 90 minutes, in advanced PD patients already receiving optimised oral medication. 33 The rapid onset of the effect of apomorphine injection has been clearly demonstrated in a prospective, randomised, double-blind, placebo-controlled, parallel-group study conducted at 26 US centres.
The investigators found significantly greater improvements in mean UPDRS motor scores in PD patients treated with apomorphine injection versus placebo 10 minutes after administration (see Figure 2 ). were taking their usual levodopa dose, dose failures were found to be surprisingly common, with 40 % having at least one during the study period. By contrast, with apomorphine injection, all but two patients achieved an ON state, 60 % of these within 20 minutes.
In terms of secondary endpoints, significant improvements were recorded in both patients' and investigators' ratings of global impression of severity of illness relative to akinesia/motor function before and after apomorphine therapy. Similar improvements were observed in measures of healthrelated QoL: EQ-5D-3L index scores were significantly reduced from a mean of 3.50 at baseline to a mean of 2.31 at the end of the 1-week apomorphine treatment period (p<0.0001) (see Figure 3) . EQ-5D-3L is a patient-reported health outcome scale related to mobility, self-care, need to be more aware of EMO symptoms and to take steps to manage them effectively in their patients using medications that avoid the oral route of administration. n
